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Abstract. Myofibroblastoma of the breast is a rare benign 
stromal tumor that occurs in both sexes with a higher 
prevalence in male breast of older populations. Furthermore, 
myofibroblastoma can arise in extra mammary sites, along 
the milk‑line. A variety of morphological variants in addi-
tion to the classic type have been identified. The differential 
diagnosis includes both benign and malignant entities that, 
through the use of clinical and radiological imaging, is 
difficult to characterize. Histopathological examination and 
immunohistochemistry are fundamental in the establishment 
of appropriate management of the disease and avoidance of 
overtreatment. The present study focuses on two cases of male 
mammary myofibroblastoma, with a short literature review.
Introduction
Mammary myofibroblastoma (MFB) is a rare benign mesen-
chymal tumor originating from mammary stromal that 
was described for the first time in 1981 (1) and first named 
by Wargotz et al in 1987 (2). Some years later, in 2001, 
McMenamin and Fletcher described the first case of extra 
mammary myofibroblastoma (MTM) (3). Both of these enti-
ties are histologically and immune‑phenotypically identical. 
Traditionally, mammary myofibroblastoma mainly affects 
older men (between 60 and 70 years), although some cases 
were also described in postmenopausal women (4). In women, 
thanks to mammary screening, this entity can be detected at a 
smaller size and, in the last few years, the incidence has been 
on the increase. Conversely, in men it is not uncommon to 
identify at diagnosis a painless and palpable mass.
MFB was described in multiple races with no predilection 
for ethnicity. Owing to its rarity, this tumor can be confused, 
both clinically and radiologically, with other types of benign 
or malignant breast cancers. Differential diagnosis is funda-
mental to avoid excessive treatment in a condition where the 
correct approach is the excision of the lesion.
In the present study, we report two cases of male mammary 
myofibroblastoma treated in the Senology Unit of the University 
Hospital of Modena (Modena, Italy) between September 2010 
and December 2018, with a short literature review.
Case reports 
Case 1. In 2010, a 65‑year‑old man presented at the Division of 
Breast Surgery of the University Hospital of Modena (Modena, 
Italy) with a palpable mass in his left breast. He had no family 
history of breast cancer, ovarian cancer or other types of 
malignancies. At the clinical examination there were no skin 
changes, no nipple changes or retraction and there were not 
lymphadenopathies at the supraclavicular or axillary sites. No 
gynecomastia was identified.
A diagnostic bilateral mammography and ultrasonog-
raphy (Fig. 1A) were performed demonstrating a nodular, 
well‑circumscribed lesion with no microcalcifications and an 
iso‑hypoechoic, oval, solid mass, respectively. The lesion occu-
pied the upper outer quadrant of the left breast and measured 
41x18 mm. The right mammography and ultrasonography were 
normal.  Fine needle aspiration cytology (FNAC) resulted in a 
suspicious specimen of malignant neoplasm (Category 4‑C4). 
Pre‑operatory abdomen and chest contrast‑enhanced computed 
tomography (CT) scan (Fig. 1B) were negative and the patient 
underwent a radical left mastectomy plus axillary dissection.
The excised mass measured 31 mm in the major axis and 
was mainly composed of epithelioid cells with some spindle 
cells, adipocytes and hyalinized collagen fibers in hematoxylin 
and eosin (H&E) stain (Fig. 2A). Some nuclear atypia were 
observed in epithelioid cells. Histopathologic examination 
also showed immunoreactivity for CD34 (Fig. 2B), desmin, 
alpha smooth muscle actin (α‑SMA) and myosin. Tumor cells 
were negative for S100, p63 and cytokeratins (Table I). The 
Ki67 proliferative index was <5%. No pathological lymph 
node was found. The immunohistochemical pattern supported 
a mammary stromal origin and the diagnosis of epithelioid 
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mammary myofibroblastoma was performed with the support 
of Professor C.D.M. Fletcher at Harvard Medical School, 
Brigham and Women's Hospital, Boston, USA.
Case 2. In 2017, a 76‑year‑old man came to our attention with 
a 13 mm oval mass in his left breast found during a chest CT 
scan (Fig. 1C). He was a strong smoker and he had a severe 
cough for a long period. This patient also had no family history 
of breast cancer, ovarian cancer or other type of malignancies. 
At clinical inspection there were no skin changes, no nipple 
changes or retraction and there were no lymphadenopathies 
at the supraclavicular or axillary sites. There were no breast 
masses or gynecomastia.
Bilateral mammogram and ultrasonography (Fig. 1D) 
showed a 15 mm oval solid mass in the retroareolar region of 
the left breast (BIRADS R5 and US5). The right mammog-
raphy and ultrasonography were normal. The subsequent 
ultrasound‑guided needle biopsy resulted in C4.
The patient underwent a radical left mastectomy and the 
removal of the sentinel lymph node. The removed mass was 
12 mm in its major axis. Histological examination in the 
H&E stain showed epithelioid and mesenchymal cells with 
hyalinized collagen fibers (Fig. 2C and D). There was no 
necrosis. Immunohistochemistry showed positive reaction 
for desmin, actin, Bcl‑2 and CD34. Neoplastic cells were also 
positive for estrogen (ER), androgen (AR) and progesterone 
(PR) receptors while S100, p63, CD99 and cytokeratins were 
negative (Table I). The Ki67 proliferative index was 1%. No 
pathological lymph nodes were identified. All of these findings 
indicated the diagnosis of myofibroblastoma.
Discussion
Myofibroblastoma is a tumor with myofibroblastic differentia-
tion, most frequently detected in men, and which represents 
the most common type of benign spindle cell lesion (1,5). 
At clinical examination, it generally presents as a unilateral, 
solitary, firm, mobile and painless breast mass with slow 
growth (6). Bilaterality and unilateral multicentricity are very 
rare. Otherwise, mammary‑type myofibroblastoma occurs 
predominantly along the embryonic milk‑line such as the axil-
lary, perianal, vulvar and para‑testicular regions (3,5,6).
Usually, the tumor mass is <40 mm but the literature also 
reports larger tumors and some cases of giant masses (around 
150‑160 mm) (7). Some patients were documented with gyne-
comastia (8) and that evidence suggests a role of the estrogen 
pathway. Interestingly, O'Bryan et al recently published the 
first case of MFB occurring in a transgender individual after 
13 months of treatment with hormone replacement therapy (9). 
In 1998, Morgan and Pitha postulated that androgen receptor 
or its ligands could be pathologically related to the develop-
ment of MFB, but the results did not resolutely prove a causal 
mechanism of hormonal tumorigenesis (10). MFB has also 
been described at the surgical scar after breast cancer exci-
sion (11), and after wide excision and radiation therapy for 
ductal carcinoma in situ (12). Several publications have also 
reported MFB in the setting of prior cancers such as prostatic, 
renal and pancreatic tumors (3,13).
Radiological features of MFB are non‑specific and it 
is often mistaken for fibroadenomas or other benign and 
malignant lesions. Breast ultrasound usually reveals a 
well‑circumscribed, oval and dense mass, with variable 
echogenicity and rare calcifications that are more common 
in cases of fibroadenoma (13‑15). The mammography shows 
a well‑circumscribed dense mass, typically round to oval 
without calcifications (14). For these reasons, immunohisto-
chemistry and histological examination play major roles in 
making the correct diagnosis.
According to the macroscopic aspect, MFB is an unen-
capsulated mass, well circumscribed from the adjacent 
parenchyma (4,6). Necrosis, hemorrhage and cystic degen-
eration are not characteristics of MFB (6). At the microscopic 
level, the classical type is composed of uniform, slender, 
spindle cells arranged in clusters separated by broad bands 
of hyalinized collagen (13). A variable adipocyte component 
and mast cells are also described. Mammary ducts and 
lobules are absent. The tumor vascular component is vari-
ably represented by small to medium‑sized vessels frequently 
showing hyalinization and foamy histiocytes in their walls. In 
most cases immunohistochemistry is positive for CD34 and 
vimentin (5,6). It is also frequently positive, with variable 
extension of immunoreactivity, for SMA, desmin, CD99, Bcl‑2, 
CD10, ER, PR and AR, while it does not express cytokeratin, 
EMA, c‑Kit (CD117), p63 and S‑100 protein (5,6). Proliferative 
activity is low with two or fewer mitoses per 10 high‑power 
fields (HPF) (5,6). In both our cases, immunohistochemical 
analysis was in line with this evidence, but for the first patient 
there was no information with regard to ER and PR status. In 
addition, there was no information regarding the expression of 
vimentin, which is typically positive in MFB.
Some case series described nuclear atypia without clinical 
consequences and, according to Howitt and Fletcher (4), 
atypical cells were present in approximately 10% of 141 MFB 
Table I. Summary of the immunohistochemical findings in our 
cases. 
Variables Case 1 Case 2
Vimentin   / /
CD34  + +
Desmin + +
Bcl‑2 / +
SMA  + +/‑
Myosin + /
ER / + (80%)
PgR / + (80%)
AR / + (98%)
CD99 / ‑
S100   ‑ ‑
Cytokeratins  ‑ ‑
Melan A / ‑
p63 ‑ ‑
α‑SMA, α‑smooth muscle actin; ER, estrogen receptor; PgR, 
progesteron receptor; AR, androgen receptor; +, positive; ‑, negative; 
/, information not available.
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Figure 1. Radiological examination of mammary myofibroblastoma. The images represent the MFB mass observed in ultrasonography in (A) the first and (D) 
second patient. Both images show a well‑circumscribed, oval, lesion. The axial imaging represents a CT scan in (B) the first and (C) second patient, with both 
patients showing a breast mass, well circumscribed. MFB, mammary myofibroblastoma; CT, computed tomography.
Figure 2. Histological examination of mammary myofibroblastoma. Fig. 2A, C and D represents myofibroblastoma cell population in H&E stain in the first 
and second patients. The lesion cells (from the first patient) are diffusely immunoreactive with CD34 (B). (A‑C) magnification, x200; (D) magnification, x400. 
H&E, hematoxylin and eosin. 
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cases reviewed. According to their histological composition, 
several patterns of MFB have been identified in addition to the 
classical type: Collagenized/fibrous, cellular, lipomatous, infil-
trative, myxoid, epitheliod and deciduoid‑like variant (5,6). 
Two different morphological patterns may potentially albeit 
rarely coexist in the same MFB.
Cytogenetic studies have shown that MFB exhibits chro-
mosome 13 rearrangements. In particular, in most cases it was 
associated with the 13q14 deletion that includes the loss of RB1 
and/or FOXO1 loci (16). These deletions have been confirmed 
by FISH analyses and were also described in spindle cell 
lipoma and in cellular angiomiofibroma, suggesting a close 
relationship among these types of lesions (16).
The principal differential diagnosis includes tumors that can 
arise primarily in the breast parenchyma such as leiomyoma, 
spindle cell lipoma, solitary fibrous tumor, spindle cell sarcoma, 
nodular fasciitis, desmoid‑type fibromatosis, angiomyolipomas, 
pseudoangiomatous stroma hyperplasia and spindle cell carci-
noma (5). In particular, the epithelioid variant can be confused 
with invasive lobular carcinoma due to the pseudo‑infiltrative 
growth pattern and the expression of ER and PR. As the name 
implies, the epitheliod variant is composed, exclusively or 
predominantly, by cells with epitheliod morphology (at least 50% 
of the entire tumor) (5) and for this reason, it is a rare subtype. 
The cases presented in this study emphasize that the correct 
diagnosis of MFB is fundamental to avoid its overtreatment. 
Generally, the absences of cytologic atypia and necrosis as well 
as the lack of high mitotic activity and atypical mitoses at the 
diagnostic biopsy are useful in the exclusion of malignancy. No 
therapies are necessary after surgical removal, since recurrence 
is unlikely following excision with clear resection margins (R0) 
and no distant metastasis has been described after a follow‑up 
period of 15 years (17).
Non‑specific imaging of this type of tumor necessitates 
the support of histopathological analysis for correct diagnosis. 
The careful analysis of cellular composition, growth pattern 
and immunoreaction should help to differentiate MFB from 
other benign or malignant tumors of the breast. In both our 
cases, patients underwent radical surgery after the only execu-
tion of fine needle aspiration cytology. No core biopsy was 
performed to help clinicians in differential diagnosis and to 
avoid overtreatment, in particular axillary dissection. For these 
reasons, a multidisciplinary approach is critical to establish the 
appropriate management. The long‑term prognosis of MFB 
is excellent and the complete surgical excision is considered 
curative, no additional therapies, such as radiation or hormonal 
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